AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00032344 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Colonoscopy
Description: Phase I - Cross-sectional; Phase II - 5 year follow-up; Phase III - 10 year follow-up
Study NCT02811757 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: tenotomy
Study NCT02811757 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: tenodesis
Study NCT02978053 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Bright light
Description: Bright light for 30 minutes during night shifts (between 2 AM and 3 AM the first night, between 3 AM and 4 AM the second night, between 4 AM and 5 AM the third night).
Study NCT02978053 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Red light
Description: Red light for 30 minutes during night shifts (between 2 AM and 3 AM the first night, between 3 AM and 4 AM the second night, between 4 AM and 5 AM the third night).
Study NCT02626858 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: extra treatment planning CT-scan
Description: Beside the standard post-operative CT-scan, an extra pre-operative CT-scan is performed.
Study NCT02917941 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ixazomib
Description: Ixazomib capsules
Study NCT02917941 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Lenalidomide capsules
Study NCT02917941 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Dexamethasone Tablets
Study NCT00105586 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Escitalopram
Description: Participants will either take 10 to 20 mg of escitalopram or placebo. Participants who wish to participate in the open-label extension receive an additional 12 weeks of escitalopram.
Study NCT00105586 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Escitalopram
Description: Participants will either take 10 to 20 mg of escitalopram or placebo. Participants who wish to participate in the open-label extension receive an additional 12 weeks of escitalopram.
Study NCT06201221 — intervention group
Intervention type: PROCEDURE
Intervention: single-port laparoscopy surgery
Description: The two groups underwent different surgical procedures.
Study NCT06201221 — intervention group
Intervention type: PROCEDURE
Intervention: multiport laparoscopy surgery
Description: The two groups underwent different surgical procedures.
Study NCT04065217 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Diode laser 980-nm
Description: Before starting the laser session, cosmetics or makeup were removed and the skin was cleaned. The area was anesthetized by the application of as EMLA lotion (lidocaine 2.5% + prilocaine 2.5%) \[ONLY MEDICAL; CAT No. R331/72394/P001\] 20 minutes before the session. During the procedure, the laser probe was held perpendicular to the lesion and a guide beam was used to direct the application. The patient wore protective eye goggles \[CE; DIR 8001100L4\]. After the session, cool air was applied to the whole region. Each patient received a maximum of six sessions, delivered at two-week intervals. Patients reported itchiness and erythema during the session.
Study NCT00675415 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Capnography
Description: Capnography: Passive measurement of carbon dioxide via a special bite block which allows graphic assessment of the subject's respiratory activity
Study NCT01642082 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Dalantercept
Description: Given SC
Study NCT01642082 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT01351025 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: atorvastatin
Description: 10 mg daily for 4 weeks, if no symptoms or lab findings suggestive of atorvastatin toxicity, dose increase to 20 mg daily from week 4- week 20
Study NCT01351025 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: atorvastatin
Description: Starting at week 24, 10 mg daily for 4 weeks. If no symptoms or lab findings suggestive of atorvastatin toxicity were found, 20 mg daily from week 28- week 44.
Study NCT01351025 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo for atorvastin
Description: One tablet once daily for 4 weeks. If no symptoms or lab findings suggestive of toxicity were found, then increase the dose to two tablets once daily.
Study NCT00615134 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: enfuvirtide [Fuzeon]
Description: 90mg sc bid
Study NCT00615134 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Optimized background ARV therapy
Description: As prescribed
Study NCT00615134 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Optimized background ARV therapy
Description: As prescribed
Study NCT02172703 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Non-invasive ICP measurement device
Description: The non-invasive ICP measurement device used in this study has been developed in the Telematic Science Laboratory at the Kaunas University of Technology, Lithuania.~The non-invasive method is based on two-depth TCD technique for simultaneously measuring flow velocities in the intracranial and extracranial segments of the ophthalmic artery (OA).
Study NCT04379037 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcutaneous Auricular Vagus Nerve Stimulation
Description: Transcutaneous vagus nerve stimulation involves stimulating the auricular branch of the vagus nerve with a imperceptible electrical current within the concha of the ear.
Study NCT04182880 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CPL-01
Description: CPL-01 will be administered
Study NCT04182880 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be administered
Study NCT03522077 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: RadAR EasyCLik plus ®-STF hemostatic pad
Description: Chitosan-based, non-woven pad with a unique, proprietary fiber structure that when hydrated with tissue fluids forms a gel-like synthetic clot in conjunction with the RadAR EasyCLik compression device
Study NCT03522077 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: TR BAND® Compression device plus ®-STF hemostatic pad
Description: Chitosan-based, non-woven pad with a unique, proprietary fiber structure that when hydrated with tissue fluids forms a gel-like synthetic clot in conjunction with the TR BAND® compression device
Study NCT03522077 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SoftSeal®-STF hemostatic pad
Description: Chitosan-based, non-woven pad with a unique, proprietary fiber structure that when hydrated with tissue fluids forms a gel-like synthetic clot
Study NCT03522077 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: VascBand™ Hemostat
Description: The VascBand™ Hemostat is an FDA-approved compression device designed to assist hemostasis of arterial, venous and hemodialysis percutaneous access sites.
Study NCT02696902 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEDI3902
Description: Participants will receive a single IV dose of MEDI3902 500 mg and 1500 mg in MEDI3902 500 mg arm and MEDI3902 1500 mg arm, respectively.
Study NCT02696902 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive a single IV dose of placebo matched to MEDI3902.
Study NCT02310451 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: blood test
Description: blood test to J0-M3-M6-M12
Study NCT03646630 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Quadratus Lumborum Block
Description: Posterior or QL block type 2 , a bolus of 0.5 ml/Kg bupivacaine 0.25%
Study NCT03646630 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Caudal Block
Description: caudal block with 1 ml/kg of bupivacaine 0.25%.
Study NCT03555825 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Hocoma ArmeoSpring
Description: A spring-loaded upper extremity exoskeleton with 3 joints and 6 degrees of freedom. Participants use the more affected upper extremity to control and engage in therapeutic games.
Study NCT03555825 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hocoma ArmeoSpring
Description: A spring-loaded upper extremity exoskeleton with 3 joints and 6 degrees of freedom. Participants use the more affected upper extremity to control and engage in therapeutic games.
Study NCT04337086 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: T4k Appliance
Description: The pre-fabricated, hard, polyurethane, pink T4K™ (Myo functional research Co., Australia) was used in the study. It consisted of: facial bows, lingual bows / tongue guard, lingual tag / tongue tag, dental channels with a pre-determined bite position and a lip bumper. In the first week, the patients were instructed to gradually increase the wearing time of the appliance during the daytime. By the second week, the patients were instructed to wear the appliance achieving at least 8 hours during sleeping. The Trainer usually needs no adjustments. The patients were asked to place it themselves inside their mouths. The distal ends of the appliance were trimmed 2-3 mm with an acrylic bur on a straight hand piece if they were too long or the patient could not keep his lips together. By the end of the first 4 weeks, the patients were wearing the appliances minimum of 1 hour during the day plus the overnight wear following the manufacturer's instructions.
Study NCT04337086 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Twin block appliance
Description: The twin block was used, and instructions were given to wear the appliance nearly full-time. Selective sequential inter-occlusal trimming was done monthly after the 2nd month in the occlusal surface of the maxillary bite blocks to clear over the mandibular molars allowing their eruption in a more favourable mesial direction and to increase the vertical dimension. Trimming was done in the fitting surface over the maxillary and mandibular premolars whenever needed to allow their full eruption and to level the occlusal plane
Study NCT03579264 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: My Viva Plan
Description: Use of the online platform, My Viva Plan, to support health and wellness.
Study NCT02456805 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Infant Formula 1
Description: Feed ab libitum
Study NCT02456805 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Infant Formula 2
Description: Feed ab libitum
Study NCT02820584 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GSC-loaded autologous dendritic cells
Study NCT01414426 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vandetanib
Description: Given PO
Study NCT01414426 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Given PO
Study NCT01414426 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: immunohistochemistry staining method
Description: Correlative studies
Study NCT01414426 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: immunohistochemistry staining method
Description: Correlative studies
Study NCT01414426 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT01414426 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT01414426 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: biopsy
Description: Correlative studies
Study NCT01414426 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: biopsy
Description: Correlative studies
Study NCT01414426 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies
Study NCT01414426 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: pharmacological study
Description: Correlative studies
Study NCT01857622 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DU-176b 15mg
Description: oral DU-176b 15mg once daily
Study NCT01857622 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DU-176b 30mg
Description: oral DU-176b 30mg once daily
Study NCT01857622 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DU-176b 60mg
Description: oral DU-176b 60mg once daily
Study NCT00874432 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: angiotensin converting enzyme inhibitor
Description: Active comparator in chronic kidney disease and age matched control will take 1x40mg per day Placebo comparator in chronic kidney disease and age matched control will take 1 placebo pill per day
Study NCT00874432 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: lisinopril
Description: 1 x 40 mg per day
Study NCT03412968 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Polysulfone Filter
Description: The intervention for this group consisted using a Polysulfone filter in order to hemofiltration in the procedure involving Cardiopulmonary Bypass (CPB).The perfusionist's role is essential during the procedure, as they control both Cardiac Output (CO) and gas exchange, depending on their action, will affect blood lactate levels.
Study NCT03412968 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Procedure/ Surgery: without Polysulfone Filter
Description: In this group, no intervention is performed during the procedure involving Cardiopulmonary Bypass (CPB)
Study NCT03200756 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sedentary Group
Description: The sedentary group undergoes a behavioral intervention to reduce sedentary behavior which includes a patient centered approach with monitoring and goal setting.
Study NCT03200756 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Exercise Group
Description: The Active Comparative group undergoes a standard clinical approach to increase exercise which is patient centered with monitoring and goal setting.
Study NCT01329809 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Recombinant Vaccinia GM-CSF; RAC VAC GM-CSF (JX-594)
Description: intratumoral or intravenous dosage: 10e9 pfu Intravenous: administered over 60 minutes Intratumoral: direct injection into a single liver lesion
Study NCT02177903 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Bair Paws Patient Adjustable Warming System
Description: Bair Paws system uses forced-air warming. This system will be used for patients randomized to active pre-warming.
Study NCT04471233 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Multimodal analgesia including pregabalin
Description: Standardized protocol for our institution with multiple medications used for pain (NSAIDs, opioids, dexamethasone) and non-narcotic spinal. Patient will be provided with an preoperative pregabalin dose and will continue medication two weeks postoperatively.
Study NCT04471233 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Multimodal analgesia not including pregabalin
Description: Standardized protocol for our institution with multiple medications used for pain (NSAIDs, opioids, dexamethasone) and non-narcotic spinal.
Study NCT02273375 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEDI4736
Study NCT02273375 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT03482297 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: automated abdominal binder
Description: The binder automatically inflates every time the participant stands up to apply a compression level of about 40 mmHg. Participants will wear the device throughout the active/sham study day.
Study NCT03482297 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham binder
Description: The binder automatically inflates every time the participant stands up to apply a compression level of about 5 mmHg. Participants will wear the device throughout the active/sham study day.
Study NCT00964457 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cetuximab
Description: cetuximab 500mg per meter square every second week
Study NCT02076074 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: accelerated partial breast irradiation
Description: Undergo HG-PBI
Study NCT02873026 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Triamcinolone Acetonide
Description: Following the repair of the open globe eye trauma, the use of Triamcinolone Acetonide will be investigated
Study NCT00926003 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Full Computerized cognitive training
Description: 8 weeks of 3 times weekly intervention for 60 min per session with the full titrating version of Captain's Log program (3 games for attention, 3 games for visual spatial working memory, 3 games for reasoning/planning
Study NCT00926003 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Limited computerized cognitive training
Description: Locked Captain's Log CCRT that rotates randomly among simplest level of computer cognitive games training. 8 weeks of 3 times weekly intervention for 60 min per session with the non-titrating version of Captain's Log program (3 games for attention, 3 games for visual spatial working memory, 3 games for reasoning/planning).
Study NCT01589562 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Megace 800mg/20ml
Description: Megestrol acetate 800mg/20ml, Suspension, Single dose
Study NCT01589562 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DW-ES(B) 625mg/5ml
Description: Megestrol acetate 625mg/5ml, Nano suspension, Single dose
Study NCT02109198 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Active CN-NINM PoNS
Description: Delivery of active stimulation of the tongue during in-person therapy sessions (1 hour) and during two home sessions (40 minutes) daily on 6 of 7 days per week (120 total sessions). Stimulation sessions will be separated by at least 4 hours.
Study NCT02109198 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Sham CN-NINM PoNS
Description: Delivery of sham stimulation of the tongue during in-person therapy sessions (1 hour) and during two home sessions (40 minutes) daily on 6 of 7 days per week (120 total sessions). Stimulation sessions will be separated by at least 4 hours.
Study NCT02698683 — intervention group
Intervention type: OTHER
Intervention: lymphocyte count
Description: lymphocyte count
Study NCT01338922 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Continuous subcutaneous insulin infusion therapy
Description: Insulin is given continuously using an insulin pump. Devices are allowed having marketing approval. Insulins are permitted with marketing approval.
Study NCT01338922 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Multiple daily injection therapy
Description: Multiple daily injection therapy with different devices and insulin types. Devices and insulin types have to have marketing approval.
Study NCT03301090 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo
Study NCT03482297 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Oral placebo will be given three times a day on the baseline day (placebo)
Study NCT03482297 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Placebo
Description: Oral placebo will be given three times a day on the baseline day (placebo)
Study NCT03482297 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midodrine
Description: A midodrine pill 10mg will be given three times a day on the standard of care study day
Study NCT03301090 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: REGN3048
Description: REGN3048 is a fully monoclonal antibody (mAbs) which binds to the S protein of MERS-CoV.
Study NCT03482297 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Midodrine
Description: A midodrine pill 10mg will be given three times a day on the standard of care study day
Study NCT03977753 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 2LVERU® or 2LVERU® JUNIOR
Description: The treatment schema consists in taking the content of one capsule a day, 15-30 minutes before breakfast, on an empty stomach, sequentially, according to capsules' numerical order: 1 through 10. When capsule number 10 is taken, capsule 1 of the next blister should be taken on the next day to continue the treatment.~The duration of treatment will be 6 months of continuous intake of the content of 1 capsule/day.
Study NCT03977753 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The treatment schema consists in taking the content of one capsule a day, 15-30 minutes before breakfast, on an empty stomach, sequentially, according to capsules' numerical order: 1 through 10. When capsule number 10 is taken, capsule 1 of the next blister should be taken on the next day to continue the treatment.~The duration of treatment will be 6 months of continuous intake of the content of 1 capsule/day.